Evaluation of pancreatic cancer treatment by optimized measles vaccine

The first phase of the trial to investigate the safety and efficacy of intratumoral administration of optimized measles virus in patients with pancreatic cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230903059342N3

Enrollment

Registered

2024-10-19

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer. Malignant neoplasm of pancreas, unspecified

Interventions

Intervention 1: Intervention group: includes patients who, in addition to standard treatment, receive the optimized measles vaccine that designed and optimized by Baqiyatullah university intraperitone

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Confirmation of the patient's cancer by a gastroenterologist Patient age 18 to 85 Absence of pregnancy Proper functioning of liver, kidney and bone marrow The ability to understand and sign the consent form by the patient and one of these cases: the patient's spouse, parent or guardian. Complying with all protocol steps including sample submission and returning to the clinical study site for subsequent visits Absence of autoimmune diseases or diseases of the immune system

Exclusion criteria

Exclusion criteria: Life-threatening acute infection Absence of any previous record that describes the doctor's treatment and orders were nor followed by patient. Using drugs that weaken the immune system Affected by any diseases that disturbs the immune system Having any previous record of organ transplantation Allergy to measles vaccine pregnancy Using other investigational treatments at the same time

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: Thermometer.;Examining changes in the patient's heart condition. Timepoint: Hourly after the start of treatment for up to 7 days. Method of measurement: Electrocardiogram.;Examining changes in the patient's breathing status. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: pulse oximeter.;Examining the amount of CEA & CA19-9 cancer antigen in the blood. Timepoint: Weekly until 3 months after the end of treatment. Method of measurement: Blood test.;Examination of tumor size. Timepoint: Weekly until 3 months after the end of treatment. Method of measurement: Sonography.	—

Measure

Time frame

Fever. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: Thermometer.;Examining changes in the patient's heart condition. Timepoint: Hourly after the start of treatment for up to 7 days. Method of measurement: Electrocardiogram.;Examining changes in the patient's breathing status. Timepoint: Hourly in the first 24 hours and then daily up to 7 days. Method of measurement: pulse oximeter.;Examining the amount of CEA & CA19-9 cancer antigen in the blood. Timepoint: Weekly until 3 months after the end of treatment. Method of measurement: Blood test.;Examination of tumor size. Timepoint: Weekly until 3 months after the end of treatment. Method of measurement: Sonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRuhollah Dorostkar

Bagheiat-allah University of Medical Sciences

R.dorost@yahoo.com+98 21 8817 0179

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026